Evidence map›Paper›PMID 42388588›Full record

ArticleCancer diagnosis & prognosis

Prognostic Impact of Skeletal Muscle Radiodensity in Advanced Urothelial Carcinoma Undergoing Avelumab Maintenance Therapy.

Nobuhiko Shimizu, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Hiroko Suzuki, Yohei Tsubouchi, Toshiharu Morikawa, Masakazu Gonda and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nobuhiko ShimizuDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Taku NaikiDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Yosuke SugiyamaDepartment of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
Aya Naiki-ItoDepartment of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Takashi NagaiDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Toshiki EtaniDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Hiroko SuzukiDepartment of Urology, Kainan Hospital, Yatomi, Japan.
Yohei TsubouchiDepartment of Urology, Konan Kosei Hospital, Konan, Japan.
Toshiharu MorikawaDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Masakazu GondaDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Maria AokiDepartment of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
Daiki IshikawaDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Ryosuke AndoDepartment of Urology, Northern Mie Medical Center Inabe General Hospital, Inabe, Japan.
Takahiro YasuiDepartment of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: A significant survival benefit was found for avelumab maintenance therapy Patients and Methods: In this retrospective study, we investigated the prognostic significance of computed tomography-derived body composition indicators in 57 patients with advanced urothelial carcinoma who received avelumab maintenance therapy after first-line platinum-based chemotherapy. These patients were from within a cohort of 85 patients who underwent first-line platinum-based chemotherapy. Patients were divided into two groups based on a low or high skeletal muscle radiodensity (SMD). Prognostic factors were determined using univariate and multivariate analyses. Results: Among patients treated with avelumab, median progression-free survival (PFS) was 6.4 months in the high SMD group Conclusion: SMD is a potential prognostic factor for advanced urothelial carcinoma cases undergoing avelumab maintenance therapy.

Indexed as

Avelumabcarcinomacomputed tomographyskeletal muscleurinary bladder

Identifiers

PMID42388588
PMCPMC13322114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.